These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34336633)

  • 1. Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio-EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy.
    Huang ZZ; Wen W; Hua X; Song CG; Bi XW; Huang JJ; Xia W; Yuan ZY
    Front Oncol; 2021; 11():583283. PubMed ID: 34336633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
    Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
    J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.
    Hua X; Li WZ; Huang X; Wen W; Huang HY; Long ZQ; Lin HX; Yuan ZY; Guo L
    Front Oncol; 2021; 11():625534. PubMed ID: 33777769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
    Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
    Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Pre-Treatment CALLY Score Combined with EBV-DNA Levels for Prognostication in Non-Metastatic Nasopharyngeal Cancer Patients: A Clinical Perspective.
    Jiang T; Sun H; Xu T; Xue S; Xia W; Xiao X; Wang Y; Guo L; Lin H
    J Inflamm Res; 2024; 17():3353-3369. PubMed ID: 38803689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of immune-inflammatory and nutrition indicators in non-metastatic nasopharyngeal carcinoma with negative plasma Epstein-Barr virus DNA.
    Weng Y; Wu L; Li Y; Wang J; Wu Z; Hong X; Liu X; Lai J; Lu J; Qiu S
    Ther Adv Med Oncol; 2024; 16():17588359241286489. PubMed ID: 39403452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.
    Sun XS; Xiao ZW; Liu SL; Sun R; Luo DH; Chen QY; Mai HQ
    Eur Radiol; 2023 May; 33(5):3682-3692. PubMed ID: 36735041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram Based on Hemoglobin, Albumin, Lymphocyte and Platelet Score to Predict Overall Survival in Patients with T3-4N0-1 Nasopharyngeal Carcinoma.
    Zhao R; Liang Z; Chen K; Zhu X
    J Inflamm Res; 2023; 16():1995-2006. PubMed ID: 37193071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
    Tang LQ; Li CF; Li J; Chen WH; Chen QY; Yuan LX; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Zhang L; Guo SS; Liu LT; Guo L; Wu YS; Luo DH; Huang PY; Mo HY; Xiang YQ; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Guo X; Zeng YX; Mai HQ; Zeng MS
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.
    Zhang N; Hou T; Zhang S; Ling J; Jiang S; Xie Y; Liu X; Hu C; Feng Y
    Heliyon; 2024 Jan; 10(2):e24804. PubMed ID: 38312571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-Reactive Protein/Albumin Ratio (CAR) as a Prognostic Factor in Patients with Non-Metastatic Nasopharyngeal Carcinoma.
    He S; Wang Y; Chen H; Yang L; Liang S; Lu L; Chen Y
    J Cancer; 2016; 7(15):2360-2366. PubMed ID: 27994675
    [No Abstract]   [Full Text] [Related]  

  • 17. Nomogram Based on Lactate Dehydrogenase-to-Albumin Ratio (LAR) and Platelet-to-Lymphocyte Ratio (PLR) for Predicting Survival in Nasopharyngeal Carcinoma.
    Peng RR; Liang ZG; Chen KH; Li L; Qu S; Zhu XD
    J Inflamm Res; 2021; 14():4019-4033. PubMed ID: 34447260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
    Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
    Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the novel nutrition-inflammation marker of lymphocyte-C-reactive protein ratio in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy.
    Hua X; Long ZQ; Wang SF; Xu F; Wang MD; Chen JY; Zhang YL; Ni WQ; Gao YS
    Front Nutr; 2023; 10():1162280. PubMed ID: 37545573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load.
    Jiang YT; Chen KH; Yang J; Liang ZG; Qu S; Li L; Zhu XD
    Front Oncol; 2021; 11():683475. PubMed ID: 34222003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.